KALA BIO
KALA
45 hedge funds and large institutions have $79.5M invested in KALA BIO in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 11 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
2% less funds holding
Funds holding: 46 → 45 (-1)
3.38% less ownership
Funds ownership: 50.01% → 46.63% (-3.4%)
47% less capital inflows, than outflows
Capital inflows: $7.51M | Capital outflows: $14.1M
57% less call options, than puts
Call options by funds: $388K | Put options by funds: $907K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$1.04M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$518K |
| 3 |
Millennium Management
New York
|
+$518K |
| 4 |
Renaissance Technologies
New York
|
+$518K |
| 5 |
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
+$518K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
-$6.99M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1.29M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.04M |
| 4 |
Jupiter Asset Management
London,
United Kingdom
|
-$920K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$777K |
KALA Hedge Fund Activity: Q3 2021 in Review
45 of the 5,732 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q3 2021, worth a combined $79.5M — down 54% from $171M a quarter earlier.
Fund positioning in KALA was balanced in Q3 2021: 11 funds opened new positions, 11 closed out, 6 added to existing stakes and 4 trimmed.
The largest buyer was State Street, adding an estimated $1.04M. The largest seller was OrbiMed, cutting an estimated $6.99M.
- 45 institutional investors held KALA BIO (KALA) as of Q3 2021, down from 46 in Q2 2021.
- Funds reported $79.5M of KALA BIO stock for Q3 2021, down 54% quarter-over-quarter.
- 11 funds opened new KALA BIO positions in Q3 2021 and 11 closed out, a net change of 0 holders.
- The largest KALA BIO buyer in Q3 2021 was State Street, an estimated $1.04M added.
- The largest KALA BIO seller in Q3 2021 was OrbiMed, an estimated $6.99M sold.
Based on aggregated 13F filings for Q3 2021.